– USA, FL – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System for the prevention of stroke, announced the appointment of Scott Ward to its Board of Directors.
“We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his insights will be invaluable as the Company rapidly approaches potential U.S. approval of CGuard Prime, the most significant value inflection point in its history. I look forward to Scott’s contributions and believe he will have an immediate impact.” said Board Chairman, Paul Stuka.About Scott R. Ward
Scott Ward most recently served as CEO and President of Cardiovascular Systems, Inc. before its acquisition by Abbott (NYSE: ABT) in April 2023. He has over 40 years of experience in the healthcare industry, including nearly 30 years at Medtronic, Inc. where he served in various leadership roles including as SVPt and President of the CardioVascular, Neurological, and Diabetes businesses. Mr. Ward is the Founder of Raymond Holdings, a firm with activities in venture capital, strategy,y and transactional advisory services for medical technology and life science companies.
Scott Ward earned his Bachelor of Science in Genetics and Cell Biology, his Master of Science in Toxicology, and his Master of Business Administration, all from the University of Minnesota.
“I am very excited to join the InspireMD Board at such a transformational time for the company,” added Scott Ward. “With an impressive body of data demonstrating the superior short- and long-term patient outcomes of its novel CGuard Prime carotid stent system, I believe that CGuard, when approved in the U.S., will quickly become a new standard-of-care for carotid intervention and stroke prevention. I look forward to working with my fellow Board members and the InspireMD leadership team to achieve this goal.”
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.
For more: https://www.inspiremd.com/en/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.